OGN Organon & Co.
Pharmaceutical Preparations · NYSE · SEC CIK 1821825 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.2%
TTM net income YoY-57.5%
TTM EPS YoY-59.2%
Revenue 3-yr CAGR-0.3%
Net income 3-yr CAGR-28.6%
Margins
Gross margin53.1%
Operating margin—
Net margin3.5%
FCF margin11.1%
EBITDA margin—
Returns
ROE20.3%
ROA1.6%
ROIC (approx.)—
Asset turnover0.45x
Leverage & solvency
Liabilities / assets91.1%
Debt / equity7.17x
Current ratio2.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.96x
Accruals ratio-4.7%
Payout ratio9.4%
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6.22B | $6.40B |
| Cost of revenue | $2.90B | $2.69B |
| Gross profit | $3.31B | $3.71B |
| R&D expense | $366.00M | $469.00M |
| SG&A expense | $1.72B | $1.76B |
| Interest expense | $504.00M | $520.00M |
| Pretax income | $425.00M | $807.00M |
| Income tax | $238.00M | -$57.00M |
| Net income | $187.00M | $864.00M |
| EPS (basic) | 0.72 | 3.36 |
| EPS (diluted) | 0.72 | 3.33 |
| Dividends declared per share | 0.34 | 1.12 |
| Weighted avg. shares (diluted) | 260.76M | 259.15M |
| Balance sheet | ||
| Cash & equivalents | $574.00M | $675.00M |
| Receivables | $1.33B | $1.36B |
| Inventory | $1.41B | $1.32B |
| Current assets | $4.35B | $4.35B |
| PP&E, net | $1.30B | $1.17B |
| Goodwill | $4.15B | $4.68B |
| Intangibles | $1.13B | $1.41B |
| Total assets | $12.87B | $13.10B |
| Current liabilities | $2.39B | $2.72B |
| Short-term debt | $16.00M | $20.00M |
| Long-term debt | $8.63B | $8.86B |
| Total debt | $8.64B | $8.88B |
| Total liabilities | $12.12B | $12.63B |
| Shareholders' equity | $752.00M | $472.00M |
| Net debt | $8.07B | $8.21B |
| Shares outstanding | 260.32M | 257.80M |
| Cash flow statement | ||
| Operating cash flow | $700.00M | $939.00M |
| Capital expenditure | $162.00M | $175.00M |
| Free cash flow | $538.00M | $764.00M |
| Investing cash flow | -$390.00M | -$513.00M |
| Financing cash flow | -$561.00M | -$368.00M |
| Depreciation & amortization | $156.00M | $132.00M |
| Stock-based compensation | $77.00M | $105.00M |
| Dividends paid | $88.00M | $297.00M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.